

# Why Don't We Use Physiology More Often in the Cath. Labo ?



**Takashi Akasaka, MD, PhD, FESC, FAPSC, FJCS**  
**Department of Cardiovascular Medicine**  
**Wakayama Medical University, Japan**





# **Disclosure Statement of Financial Interest**

## **Takashi Akasaka, MD, PhD**

**Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.**


- **Grant/Research Support** : Abbott Vascular Japan  
Boston Scientific Japan  
Nipro Inc.  
Terumo Inc.
- **Consulting Fees/Honoraria** : Abbott Vascular Japan  
Daiichi-Sankyo Pharmaceutical Inc.  
Nipro Inc.  
Terumo Inc.




# Clinical Evidence in FFR

## Intracoronary imaging & physiology in ESC guideline 2014


**DEFER:** J Am Coll Cardiol 2007;49:2105-2111



**FAME I:** New Engl J Med 2009;360:213-224



**FAME II:** New Engl J Med 2014;371:1208-1218



Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
FFR to identify haemodynamically relevant coronary lesion(s) in stable patients when evidence of ischaemia is not available.	I	A	50,51,713
FFR-guided PCI in patients with multivessel disease.	IIa	B	54
IVUS in selected patients to optimize stent implantation.	IIa	B	702,703,706
IVUS to assess severity and optimize treatment of unprotected left main lesions.	IIa	B	705
IVUS or OCT to assess mechanisms of stent failure.	IIa	C	
OCT in selected patients to optimize stent implantation.	IIb	C	

Eur Heart J. 2014;35:2541-2619

Wakayama Medical University

# 2018 ESC/EACTS Guidelines on myocardial revascularization

The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association of Cardio-Thoracic Surgery (EACTS)

Developed with the special contribution of the European Association for Percutaneous Cardiovascular Intervention (EAPCI)

**Authors/Task Force Members:** Franz-Josef Neumann (Germany), Miguel Sousa-Uva\*<sup>1</sup> (EACTS Co-ordinator) (Sweden), Fernando Alfonso (Spain), Adriaan A. van der Giet (UK), Robert A. Byrne (Germany), Jean-Philippe Collet (Germany), Stuart J. Head<sup>1</sup> (The Netherlands), Adnan Kastrati (Germany), Akos Koller (Hungary), Josef Niebauer (Austria), Dimitrios J. Richter (Germany), Dirk Sibbing (Germany), Giulio G. Stefanini (Switzerland), Rashmi Yadav<sup>1</sup> (UK), Michael J. B. de Waard (UK)


**Document Reviewers:** William Wijns (ESC Review Co-ordinator) (Canada), Victor Aboyans (France), Steffen Ege (Norway), Felicita Andreotti (Italy), Emanuele Barbato (Canada), Héctor Bueno (Spain), Patrick A. Calvert (UK)

## Recommendations on functional testing and intravascular imaging for lesion assessment

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
When evidence of ischaemia is not available, FFR or iwFR are recommended to assess the haemodynamic relevance of intermediate-grade stenosis. <sup>15,17,18,39</sup>	<b>I</b>	<b>A</b>
FFR-guided PCI should be considered in patients with multivessel disease undergoing PCI. <sup>29,31</sup>	<b>IIa</b>	<b>B</b>
IVUS should be considered to assess the severity of unprotected left main lesions. <sup>35–37</sup>	<b>IIa</b>	<b>B</b>



# Global Adoption of Coronary Physiology to Guide Revascularization Decision Making in 2016



# Why Don't We Use Physiology More Often in the Cath. Labo?

## Coronary Psychology

### Do You Believe?\*

Nils P. Johnson, MD, MS,<sup>a</sup> Bon-Kwon Koo, MD, PhD<sup>b</sup> **J Am Coll Cardiol Interv 2018;11:1492-1494**

claimed it was due to a knowledge barrier (“I do not understand enough about FFR”). Additionally, <5% of responses identified attitude barriers, for example “I do not trust FFR.” Instead, the dominant responses focused on reimbursement and the time necessary to perform the procedure. A logical conclusion from this survey was that we should focus on environmental barriers to improve the penetrance of coronary physiology.




# Why Don't We Use Physiology More Often in the Cath. Labo?

- **Re-imburement issue: insurance coverage**
- **Oculo-stenotic reflex: Many interventionist might be anatomy first more than physiology as angio-believers.**
- **Difficulty to understand the concept of coronary physiology completely.**
- **Difficulty of the wire manipulation compared with other work force wires.**
- **Patients discomfort & time consuming procedure.**




# FFR market in Japan





# Recent PGW market in Japan (Yano Keizai)



Source: 2009~2017 Yano Keizai, 2018 estimate

Wakayama Medical University



# Public Reporting of Coronary Physiology Uptake

Johnson NP & Koo BK. J Am Coll Cardiol Interv 2018;11:1492-1494

Country (Ref. #)	Year	PW	PCI	PW/PCI	Temporal Change	Hospital-Level Reporting?
Sweden (9)	2017	NR	NR	26%	3.1-fold in 10 yrs	Yes
United Kingdom (10)	2016	18,811	100,483	19%	3.5-fold in 8 yrs	Yes
Italy (11)	2016	11,000	218,751	5%	1.4-fold in 4 yrs	Yes
Europe EAPCI (12)	2015	NR	889,957	16%	2-fold in 5 yrs	Per country
United States (13)	2014	3,465*	NR	31%	3.8-fold in 5 yrs	No
Australia (14)	2015	NR	3,869	19%	100-fold in 9 yrs	Per state

\*Limited to a subset of the 59,375 patients in the National Cardiovascular Data Registry CathPCI Registry with lesions deemed 40-70% by visual assessment.

EAPCI = European Association of Percutaneous Cardiovascular Interventions; NR = not reported; PCI = percutaneous coronary intervention; PW = intracoronary pressure wire.



# Why Don't We Use Physiology More Often in the Cath. Labo?

- Re-imburement issue: insurance coverage
- Oculo-stenotic reflex: Many interventionist might be anatomy first more than physiology as angio-believers
- Difficulty to understand the concept of coronary physiology completely.
- Difficulty of the wire manipulation compared with other work force wires.
- Patients discomfort & time consuming procedure.



# Anatomy can predict physiology ?


Table 3. Summary of Literature Predicting Physiology From Minimum Lumen Area

Method	FFR Reference	Reference	Stenoses, n	Best MLA Cutoff, mm <sup>2</sup> *	Area Under ROC Curve	Correlation
3D-QCA	<0.8	Yong et al <sup>17</sup>	63	1.9	0.79	0.63
IVUS	≤0.8	Koh et al <sup>48</sup>	55	1.8	0.70	0.30
	≤0.8	Gonzalo et al <sup>56</sup>	61	2.4	0.63	
	≤0.8	Gonzalo et al <sup>56</sup>	61	2.4	0.63	0.10
	<0.8	Park et al <sup>41</sup>	1066	2.4	0.76	0.47
	<0.8	Kang et al <sup>47</sup>	784	2.4	0.77	0.48
	<0.8	Kang et al <sup>57</sup>	236	2.4	0.80	0.51
	<0.8	Koo et al <sup>46</sup>	267	2.8		
	<0.8	Chen et al <sup>58</sup>	323	3.0	0.77	
	<0.75	Takagi et al <sup>50</sup>	51	3.0		0.79
	<0.8	Kwan et al <sup>59</sup>	169	3.0	0.86	0.50
	<0.8	Waksman et al <sup>55</sup>	367	3.1	0.65	0.30
	<0.8	Ben-Dor et al <sup>60</sup>	205	3.1	0.73	0.36
	<0.8	Ben-Dor et al <sup>61</sup>	92	3.2	0.74	0.34
	≤0.8	Koh et al <sup>48</sup>	38	3.5	0.82	0.55
	<0.75	Briguori et al <sup>62</sup>	53	4.0		0.41
	<0.8	Park et al <sup>41</sup>	63	4.8†	0.83	0.56
	<0.8	Kang et al <sup>43</sup>	55	4.8†	0.90	0.62
	<0.75	Jasti et al <sup>63</sup>	55	5.9†		0.74
	<0.75	Lee et al <sup>54</sup>	86		0.87	





# Anatomy can predict physiology ?



## OPUS-CLASS study

*Kubo T, et al. JACC Cardiovasc Img. 2013;6:1095-1104*

Much better accuracy in the measurement has been demonstrated in OCT compared with IVUS.

**Table 3. Summary of Literature Predicting Physiology From Minimum Lumen Area**

Method	FFR Reference	Reference	Stenoses, n	Best MLA Cutoff, mm <sup>2</sup> *	Area Under ROC Curve	Correlation
OCT	≤0.8	Reith et al <sup>44</sup>	62	1.6	0.81	0.62
	<0.75	Shiono et al <sup>64</sup>	62	1.9	0.90	0.75
	<0.75	Shiono et al <sup>64</sup>	62	1.9	0.90	0.75
	≤0.8	Gonzalo et al <sup>56</sup>	61	2.0	0.74	
	≤0.8	Gonzalo et al <sup>56</sup>	61	2.0	0.74	0.33

Several randomised studies and meta analysis demonstrated that there are moderate correlation between anatomical and physiological lesion severity assessment, and optimal cut-off value of FFR < 0.80 should be vessel dependent.



# Multivariable logistic regression analysis

## For functionally significant stenosis (FFR<0.75)

*Shiono Y, et al. Catheter Cardiovasc Interv. 2014;84:406-413*

	OR	95% CI	p value
Minimal lumen diameter	0.022	0.007-0.062	<0.001
Lesion length	1.049	1.020-1.079	= 0.001
Supply area (modified APPROACH score)	1.102	1.068-1.137	<0.001

OR = odds ratio; CI = confidence interval; LAD = left anterior descending coronary artery; APPROACH score = Alberta Proivincia Project for Outcome Assessment in Coronary Heart Disease score



# Fighting the “Oculostenotic Reflex”

Grace A. Lin, MD, MAS; R. Adams Dudley, MD, MBA



**JAMA Internal Medicine 2014;174:1621-1622**

In recent studies, a major reason for current practice. Many physicians are influenced by the so-called oculostenotic reflex, in which any significant stenosis seen during the catheterization is subject to treatment, even if evidence suggests no benefit. In focus groups conducted in 2007,<sup>4(p1606)</sup> cardiologists described how patients “could not escape” a procedure once they were in the catheterization laboratory. One physician stated, “I think we all know that we’re not necessarily preventing heart attacks by treating asymptomatic stenosis...but nonetheless that patient leaves the lab with an open artery, the best that my interventional partners can offer.” The medical culture appears to reinforce this cognitive bias toward intervention, resulting in non-evidence-based treatment decisions.



# Oculostenotic Reflex

Integrated Lacrimal Functional Unit






# Lesion assessment in FAME Study Angiography vs FFR


Tonino PAL, et al. J Am Coll Cardiol 2010;55:2816-2821

Number of functionally diseased vessels (0-, 1-, 2-, or 3-VD) as proportions of all patients with angiographic 2-VD (n=394)



**Angiographic 2-VD**

Number of functionally diseased vessels (0-, 1-, 2-, or 3-VD) as proportions of all patients with angiographic 3-VD (N=115)\*



**Angiographic 3-VD**

**There might be concern about the reduction of PCI number if physiological assessment has to be performed frequently.**



# Why Don't We Use Physiology More Often in the Cath. Labo?

- **Re-imburement issue: insurance coverage**
- **Oculo-stenotic reflex: Many interventionist might be anatomy first more than physiology as angio-believers**
- **Difficulty to understand the concept of coronary physiology completely.**
- **Difficulty of the wire manipulation compared with other work force wires.**
- **Patients discomfort & time consuming procedure.**



# Measurement of FFRmyo

No stenosis

$P_a$

FFR(A)= Max flow under the condition  
with stenosis / without stenosis

$P_d$

During HE;  $P_d = P_a$   
 $P_d / P_a = 1.0$

Stenosis (A)

$P_a$

$P_d$

FFR (A) =  $P_d / P_a$  during HE

Rest  $P_d < P_a$ ,  
During HE  $P_d \ll P_a$



# Concept of FFRmyo

First, it will be pressure ( $P_a$ ) and subtraction of venous pressure ( $P_v$ ), that  $R_s = \infty$  and  $P_d = P_w$  by definition.

Because  $Q_c^N = 0$ :

The contribution calculated as follows:

Note that for evaluation of stenotic artery after PTCA, a better measure than  $FFR$  is independent of arterial pressure.

Finally, the theoretical relation between collateral flow at different degrees of stenosis can be obtained. From Figure 1, it is clear that  $Q_c = (P_a - P_d)/R_c$ . Therefore:

Therefore:

$$\frac{FFR_{cor}^{(2)}}{FFR_{cor}^{(1)}} = \frac{P_d^{(2)} - P_w^{(2)}}{P_d^{(1)} - P_w^{(1)}}$$

$$\frac{Q_c^{(2)}}{Q_c^{(1)}} = \frac{(P_a^{(2)} - P_d^{(2)})/R_c}{(P_a^{(1)} - P_d^{(1)})/R_c} = \frac{\Delta^{(2)}P}{\Delta^{(1)}P} \quad (A7a)$$

or, if correction for pressure changes is made:

and

and because  $Q_s^N =$

$$= \left( 1 - \frac{\Delta}{P_a^{(2)}} \right)$$

$$\frac{Q_c^{(2)}}{Q_c^{(1)}} = \frac{\Delta^{(2)}P}{P_a^{(2)} - P_v^{(2)}} \cdot \frac{\Delta^{(1)}P}{P_a^{(1)} - P_v^{(1)}} \quad (A7b)$$

Therefore

Substitution of Equation A1b, gives the following:

In case of interventional maximum vasodilation, pressure  $P_a - P_v$  through the coronary intervention (situation).

The expression  $FFR_{cor}$  of the dilated pressure-corrected  $FFR$  is called pressure-corrected  $FFR$ . Equation A5a can be applied in the following:

In fact, Equation A7 states that decrease of  $\Delta P$  by improved stenosis geometry after PTCA induces a proportional decrease of the relative contribution of collateral flow to total myocardial flow, which will be further clarified in the following examples.

Application of these equations in clinical practice also will be demonstrated.

Equation A1a can be used, which will be

$FFR_{cor} =$

$$\frac{Q_s^{(2)}}{Q_s^{(1)}} = \frac{Q_c^{(2)} - Q_c^{(1)}}{Q_c^{(1)} - Q_c^{(2)}} \quad \text{Example 1}$$

and by substituting Equation A6b, maximum myocardial flow can be compared.

The first example is based on the simple hemodynamic case in which systemic pressures ( $P_a$  and  $P_v$ ) are unchanged during PTCA. Therefore, according to Equation A1a, wedge pressure ( $P_w$ ) also is constant.

Before and after PTCA of one of the coronary arteries, (pressure measurements are performed by the pressure-monitoring guide wire at maximum coronary hyperemia induced by intracoronary administration of papaverine or adenosine. Mean arterial pressure ( $P_a$ ) is 90 mm Hg both before and after the procedure; transstenotic pressure gradient  $\Delta P$  is reduced from 50 mm Hg before to 10 mm Hg after the procedure; and venous pressure ( $P_v$ ) is 0 mm Hg both before and after the procedure.  $P_w$  measured during balloon inflation, is 20 mm Hg. Therefore,  $P_a^{(1)} = P_a^{(2)} = 90$  mm Hg,  $P_d^{(1)} = 40$  mm Hg,  $P_d^{(2)} = 80$  mm Hg,  $P_v^{(1)} = P_v^{(2)} = 0$  mm Hg, and  $P_w^{(1)} = P_w^{(2)} = 20$  mm Hg.

or, if correction for pressure changes is made:

$$\frac{FFR_{myo}^{(2)}}{FFR_{myo}^{(1)}} = \frac{P_d^{(2)} - P_v^{(2)}}{P_d^{(1)} - P_v^{(1)}}$$

With Equations A6b, A5b, and A7b, the following is obtained:

By substitution

$FFR_{myo} =$

Next, fractional flow calculated as follows:


where  $C_1$ ,  $C_2$ , and collateral resistance of the stenotic coronary bed supplied to the myocardium.

Equation A3 has






# Wave free period & iFR



# Coronary Autoregulation as a Means of Quantifying Stenosis Severity Under Resting Conditions




Göteborg M, et al. J Am Coll Cardiol 2017;70:1379-1402

Wakayama Medical University



# Coronary Autoregulation as a Means of Quantifying Stenosis Severity Under Resting Conditions




Göteborg M, et al. J Am Coll Cardiol 2017;70:1379-1402

Wakayama Medical University



# DEFINE-FLAIR

## Cumulative Risk of the Primary Endpoint




### No. at Risk

iFR	1242	1149	1131	1122	1118	1111	1088	1052	1037	1027	1019	995	764
FFR	1250	1169	1156	1149	1144	1141	1119	1081	1066	1055	1046	1017	793

**Davies JE, et al. N Engl J Med 2017;376:1824-34.**

# SWEDHEART

## Kaplan-Meier Curve for the Primary Endpoint



### No. at Risk

iFR	1012	1002	984	971	963	956	944
FFR	1007	990	984	976	968	961	946

**Göteborg M, et al. N Engl J Med 2017;376:1813-23.**


# Comparison among coronary physiology measurement

System	Abbott	Acist	Boston	Opsens	Philips
Type of Sensor	Piezo-Electric	Optical	Optical	Optical	Piezo-Electric
Torqueability	△	N/A	○	◎	△
Drift	△	○	○	◎	△
Reconnection	△	N/A	○	◎	△
Display	◎	△	○	△	○
Evidence	◎	△	△	△	○
Flow data	◎	-	-	-	○
Co-registration	-	-	-	-	◎
Resting index	RFR	dPR	DFR	dPR	iFR







# Different diastolic indexes




— Pa — Pd


# Comparison among different diastolic indexes & iFR



Diagnostic Values of Diastolic Indexes at Cutoff Value  
of  $\leq 0.89$  Versus FFR 0.8





**CENTRAL ILLUSTRATION: Correlations and AUC Values >0.99 for All Resting Pd/Pa Ratios Over Different Periods in Diastole Compared With iFR as the Reference Standard**






van't Veer, M. et al. J Am Coll Cardiol. 2017;70(25):3088-96.

# PCI case with iFR co-registration






# Prediction of post PCI iFR by Syncvision




**VOLCANO**  
PRECISION GUIDED THERAPY

**VOLCANO**  
PRECISION GUIDED THERAPY



# Prediction of post PCI iFR by Syncvision





We chose a short stent.



# iFR Pullback



# The Expected Behavior of Hyperemic and Resting Flow After Removal of Stenosis



Göteborg M, et al. J Am Coll Cardiol 2017;70:1379-1402



# Why Don't We Use Physiology More Often in the Cath. Labo?

- **Re-imburement issue: insurance coverage**
- **Oculo-stenotic reflex: Many interventionist might be anatomy first more than physiology as angio-believers**
- **Difficulty to understand the concept of coronary physiology completely.**
- **Difficulty of the wire manipulation compared with other work force wires.**
- **Patients discomfort & time consuming procedure.**





# Comparison among coronary physiology measurement

System	Abbott	Acist	Boston	Opsens	Philips
Type of Sensor	Piezo-Electric	Optical	Optical	Optical	Piezo-Electric
Torqueability	△	N/A	○	◎	△
Drift	△	○	○	◎	△
Reconnection	△	N/A	○	◎	△
Display	◎	△	○	△	○
Evidence	◎	△	△	△	○
Flow data	◎	-	-	-	○
Co-registration	-	-	-	-	◎
Resting index	RFR	dPR	DFR	dPR	iFR



# Why Don't We Use Physiology More Often in the Cath. Labo?

- Re-imburement issue: insurance coverage
  - Oculo-stenotic reflex: Many interventionist might be anatomy first more than physiology as angio-believers
  - Difficulty to understand the concept of coronary physiology completely.
  - Difficulty of the wire manipulation compared with other work force wires.
- Patients discomfort & time consuming procedure.



# Procedural Characteristics (DEFINE-FLAIR)

## Superiority of iFR to FFR

Variable	iFR Group (N= 1242)	FFR Group (N= 1250)	P Value†
Stents placed with postdilation — no. (% of total stents placed)	407 (49.5)	425 (46.9)	0.28
PCI procedures performed with pressure wire — no. (% of total stents placed)	261 (31.8)	278 (30.7)	0.63
Patient-reported adverse procedural symptoms or signs — no. of patients (%)	39 (3.1)	385 (30.8)	<0.001
Patient-reported dyspnea — no. of patients (%)	13 (1.0)	250 (20.0)	
Patient-reported chest pain — no. of patients (%)	19 (1.5)	90 (7.2)	
Physician-reported adverse procedural signs — no. of patients (%)			
Heart-rhythm disturbance	2 (0.2)	60 (4.8)	
Significant hypotension	4 (0.3)	13 (1.0)	
Vomiting or nausea	1 (0.1)	11 (0.9)	
Ventricular arrhythmia or bronchospasm¶	1 (0.1)	8 (0.6)	
Other	4 (0.3)	38 (3.0)	

# Procedural Characteristics (DEFINE-FLAIR)

## Superiority of iFR to FFR

Variable	iFR Group (N = 1242)	FFR Group (N = 1250)	P Value†
Radial-artery approach — no. of patients (%)	896 (72.1)	888 (71.0)	0.54
Procedure time — min			
Median	40.5	45.0	0.001
Interquartile range	27.0–60.0	30.0–66.0	
Hyperemic agent administered — no. of patients (% of total no. who received a hyperemic agent)			
Total	NA	1608 (100)	
Intracoronary adenosine	NA	455 (28.3)	
Intravenous adenosine	NA	950 (59.1)	
Other agent	NA	203 (12.6)	
Multivessel disease — no. of patients (%)	505 (40.7)	519 (41.5)	0.66
Type of vessel evaluated — no. (% of total vessels evaluated)‡			
Total	1575 (100)	1608 (100)	0.58
Left anterior descending artery	844 (53.6)	845 (52.5)	0.56
Left circumflex artery	323 (20.5)	333 (20.7)	0.89
Right coronary artery	374 (23.7)	393 (24.4)	0.65
Other	33 (2.1)	31 (1.9)	0.74
Unknown	1 (0.1)	6 (0.4)	0.06



# Procedural Characteristics (SWEDEHEART)

## Superiority of iFR to FFR

Characteristic	iFR Group (N=1012)	FFR Group (N=1007)	P Value
Radial-artery approach — no. of patients (%)	841 (83.1)	811 (80.5)	0.13
Contrast material used per patient — ml			0.10
Median	110	115	
Interquartile range	80–155	80–160	
Procedure time — min†			0.09
Median	50.8	53.1	
Interquartile range	13.8–87.8	18.1–88.1	
Fluoroscopy time — min			0.57
Median	10.5	10.2	
Interquartile range	6.3–16.8	6.5–16.0	
Intravenous adenosine administered — no. of patients (%)	NA	695 (69.0)	
Total no. of lesions evaluated	1568	1436	
Chest discomfort during procedure			<0.001†
None	982 (97.0)	319 (31.7)	
Mild	26 (2.6)	316 (31.4)	
Moderate	2 (0.2)	285 (28.3)	
Severe	2 (0.2)	87 (8.6)	





# 2018 ESC/EACTS Guidelines on myocardial revascularization

The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association of Cardio-Thoracic Surgery (EACTS)

Developed with the special contribution of the European Association for Percutaneous Cardiovascular Intervention (EAPCI)

**Authors/Task Force Members:** Franz-Josef Neumann (Germany), Miguel Sousa-Uva\*<sup>1</sup> (EACTS Co-ordinator) (Sweden), Fernando Alfonso (Spain), Adriaan van der Giet (UK), Robert A. Byrne (Germany), Jean-Philippe Collet (Germany), Stuart J. Head<sup>1</sup> (The Netherlands), Adnan Kastrati (Germany), Akos Koller (Hungary), Josef Niebauer (Austria), Dimitrios J. Richter (Germany), Dirk Sibbing (Germany), Giulio G. Stefanini (Switzerland), Rashmi Yadav<sup>1</sup> (UK), Michael J. B. de Waard (The Netherlands)

**Document Reviewers:** William Wijns (ESC Review Co-ordinator) (Canada), Victor Aboyans (France), Steffen Ege (Norway), Felicita Andreotti (Italy), Emanuele Barbato (Canada), Héctor Bueno (Spain), Patrick A. Calvert (UK)

## Recommendations on functional testing and intravascular imaging for lesion assessment

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
When evidence of ischaemia is not available, FFR or iwFR are recommended to assess the haemodynamic relevance of intermediate-grade stenosis. <sup>15,17,18,39</sup>	I	A
FFR-guided PCI should be considered in patients with multivessel disease undergoing PCI. <sup>29,31</sup>	IIa	B
IVUS should be considered to assess the severity of unprotected left main lesions. <sup>35–37</sup>	IIa	B

# Why Don't We Use Physiology More Often in the Cath. Labo?

## Coronary Psychology

J Am Coll Cardiol Interv 2018;11:1492-1494

### Do You Believe?\*

Nils P. Johnson, MD, MS,<sup>a</sup>

don't interventional cardiologists use coronary physiology?" As demonstrated by both virtual (4) and real-world (2) studies, and large temporal increases in its uptake (**Table 1**), factors such as cost, reimbursement, need for hyperemic drugs or pressure sensor design and delivery play minor roles. Although operators can be reluctant to admit it (3), the fundamental reason has received different labels: attitude, belief, local practice "experience," and culture. Put simply, we as a profession do not yet emotionally accept coronary physiology to guide treatment. Call it "coronary psychology."



# Take home message

**Why Don't We Use Physiology More Often in the Cath. Labo ?**

**My private opinion with no scientific evidence!!**

- There are many issues which lead the interventionists not to use physiology so often in the cath. labo.

Re-imburement & income

Difficulty of coronary physiology concept

# Let's Use Physiology !!

- There are still many visual first PCI physicians who are anatomy believer and staying in fantastic illusion world where PCI can improve patients prognosis even in stable coronary artery disease, and they cannot escape from the addiction of oculo-stenotic reflex.





# Change Practice!! JCS2020

The 84th Annual Scientific Meeting  
of the Japanese Circulation Society

**March 13(Fri)-15(Sun), 2020**

Venue

- ▶ Kyoto International Conference Center
- ▶ Grand Prince Hotel Kyoto

Congress Chairperson

**Takeshi Kimura, M.D., Ph.D.**

Professor, Department of Cardiovascular Medicine,  
Kyoto University Graduate School of Medicine, Kyoto

*2020 Kyoto*

Evolution & Collaboration

## APSC2020

Asian Pacific Society of Cardiology Congress 2020

**March 12(Thu)-14(Sat), 2020**

Venue

- ▶ Kyoto International Conference Center
- ▶ Grand Prince Hotel Kyoto

Congress Chairperson

**Takashi Akasaka, M.D., Ph.D.**

Professor, Department of Cardiovascular Medicine,  
Wakayama Medical University, Wakayama

Congress Secretariat c/o Congress Corporation

3-6-13 Awajimachi, Chuo-ku, Osaka 541-0047, Japan

Tel: +81-6-6229-2555 Fax: +81-6-6229-2556

E-mail: [jcs2020@congre.co.jp](mailto:jcs2020@congre.co.jp) / [apsc2020@congre.co.jp](mailto:apsc2020@congre.co.jp)


**Thank you for your kind attention !!**



**Welcome to APSC 2020 in Kyoto,  
Japan!!**

**Wakayama Medical University**

# iFR



## Validation of a novel non-hyperaemic index of coronary artery stenosis severity: the Resting Full-cycle Ratio (VALIDATE RFR) study

Johan Svanerud<sup>1</sup>, MSc; Jung-Min Ahn<sup>2</sup>, MD; Allen Jeremias<sup>3,4</sup>, MD; Marcel van 't Veer<sup>5,6</sup>, MSc, PhD; Ankita Gore<sup>3,7</sup>, BS, MSc; Akiko Maehara<sup>3,7</sup>, MD; Aaron Crowley<sup>3</sup>, MA; Nico H.J. Pijls<sup>5,6</sup>, MD, PhD; Bernard De Bruyne<sup>8</sup>, MD, PhD; Nils P. Johnson<sup>9</sup>, MD, MS; Barry Hennigan<sup>10</sup>, MD; Stuart Watkins<sup>10</sup>, MD; Colin Berry<sup>10,11</sup>, MD, PhD; Keith G. Oldroyd<sup>10</sup>, MD; Seung-Jung Park<sup>2</sup>, MD, PhD; Ziad A. Ali<sup>3,7\*</sup>, MD, DPhil

1. Corvenit Research AB, Uppsala, Sweden; 2. Asan Medical Center, Seoul, South Korea; 3. Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, USA; 4. St. Francis Hospital, Roslyn, NY, USA; 5. Catharina Hospital, Eindhoven, the Netherlands; 6. Eindhoven University of Technology, Department of Biomedical Engineering, Eindhoven, the Netherlands; 7. New York-Presbyterian Hospital/Columbia University Medical Center, New York, NY, USA; 8. The Cardiovascular Center, OLV Hospital, Aalst, Belgium; 9. Weatherhead PET Center, Division of Cardiology, Department of Medicine, McGovern Medical School at UTHealth and Memorial Hermann Hospital, Houston, TX, USA; 10. Golden Jubilee National Hospital, Clydebank, United Kingdom; 11. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom

### KEYWORDS

- fractional flow reserve
- innovation
- other imaging modalities

### Abstract

**Aims:** Randomised controlled trials have reported instantaneous wave-free ratio (iFR) to be non-inferior to fractional flow reserve (FFR) for major adverse cardiovascular events at one year; however, iFR is limited by sensitive landmarking of the pressure waveform, and the assumption that maximal flow and minimal resistance occur during a fixed period of diastole. We sought to validate the resting full-cycle ratio (RFR), a novel non-hyperaemic index of coronary stenosis severity based on unbiased identification of the lowest distal coronary pressure to aortic pressure ratio (Pd/Pa), independent of the ECG, landmark identification, and timing within the cardiac cycle.

**Methods and results:** VALIDATE-RFR was a retrospective study designed to derive and validate the RFR. The primary endpoint was the agreement between RFR and iFR. RFR was retrospectively determined in 651 waveforms in which iFR was measured using a proprietary Philips/Volcano wire. RFR was highly correlated to iFR ( $R^2=0.99$ ,  $p<0.001$ ), with a mean bias of  $-0.002$  (95% limits of agreement  $-0.023$  to  $0.020$ ). The diagnostic performance of RFR versus iFR was diagnostic accuracy 97.4%, sensitivity 98.2%, specificity 96.9%, positive predictive value 94.5%, negative predictive value 99.0%, area under the receiver operating characteristic curve of 0.996, and diagnostically equivalent within 1% (mean difference  $-0.002$ ; 95% CI:  $-0.009$  to  $0.006$ ,  $p=0.03$ ). The RFR was detected outside diastole in 12.2% (341/2,790) of all cardiac cycles and 32.4% (167/516) of cardiac cycles in the right coronary artery where the sensitivity of iFR compared to FFR was lowest (40.6%).

**Conclusions:** RFR is diagnostically equivalent to iFR but unbiased in its ability to detect the lowest Pd/Pa during the full cardiac cycle, potentially unmasking physiologically significant coronary stenoses that would be missed by assessment dedicated to specific segments of the cardiac cycle.

\*Corresponding author: Columbia University Medical Center; Cardiovascular Research Foundation; 1700 Broadway, 9th Floor; New York, NY 10019; USA. E-mail: zaa2112@columbia.edu

© Europa Digital & Publishing 2018. All rights reserved.

SUBMITTED ON 30/03/2018 - REVIEW RECEIVED ON 14/04/2018 / 27/05/2018 - ACCEPTED ON 09/05/2018

# Validation of a novel non-hyperemic index of coronary artery stenosis severity - the Resting Full-cycle Ratio (RFR) - VALIDATE RFR

J Svanerud, JM Ahn, A Jeremias, M van 't Veer, A Gore, A Maehara, A Crowley, N. Pijls, B De Bruyne, N Johnson, B Hennigan, S Watkins, C Berry, KG Oldroyd, SJ Park, ZA. Ali







# Resting Full-cycle Flow Ratio (RFR)

## Lowest Pd/Pa ratio during the entire heart cycle

- Unbiased identification of lowest Pd/Pa in diastole or systole
- Independent of ECG
- No waveform landmark identification necessary
- Sensitive to small pressure changes during pullback
- High dynamic range



# Resting Full-cycle Flow Ratio (RFR)



- 4-5 consecutive heart cycles used to determine the RFR

